Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on June 13, 2013. The report announces the issuance of a press release detailing financial results for the fiscal quarter and fiscal year ended March 31, 2013. The full text of the press release is included as Exhibit 99.1 but is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the body text. It directs readers to the attached press release for the comparison of results for the quarter and year ended March 31, 2013.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The report contains statements regarding intentions, beliefs, expectations, and strategies, including a planned spin-off of a separate public company.
- Key Risks: Management highlights uncertainties associated with effecting the spin-off. The Board of Directors retains the discretion to delay or cancel the spin-off prior to execution.
- Disclaimer: Actual outcomes may differ materially from forecasts due to risks discussed in the Company's Annual Report on Form 10-K. The Company does not undertake an obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the specific financial results (revenue, net income, cash position) by reviewing Exhibit 99.1 (the press release), as these numbers are absent from the 8-K body text.
- Confirm the current status of the planned spin-off and whether the Board has exercised discretion to delay or cancel it.
- Review the most recent Form 10-K for a comprehensive list of risk factors beyond those summarized in this report.
- Note the discrepancy between the requested company name (Sonoma Pharmaceuticals) and the actual registrant (Oculus Innovative Sciences).